New hope for kidney cancer: early trial of KSD-201 begins
Disease control
Not yet recruiting
This early-phase study tests a new drug called KSD-201 in 12 people with advanced clear cell renal cell carcinoma who have not responded to standard treatments. The main goal is to check the drug's safety and side effects, while also looking at how well it controls the cancer and…
Phase: EARLY_PHASE1 • Sponsor: Kousai Bio Co., Ltd. • Aim: Disease control
Last updated May 04, 2026 16:24 UTC